Loading...
Treatment of high-grade cervical intraepithelial neoplasia (CIN 2–3) has traditionally involved excisional procedures, particularly in women aged ≥30. Austrian researchers conducted a manufacturer-supported, double-blind phase II trial to investigate the efficacy of topical imiquimod as a medical alternative in 59 women (aged ≥18) with high-risk human papillomavirus (HPV) infection and histologically confirmed CIN 2–3. Participants were randomized to self-insertion of vaginal suppositories containing 6.25-mg imiquimod or placebo for 16 weeks; dosing escalated from one to three suppositories weekly. At 8 weeks, colposcopy with biopsy of the initial lesion site was performed.
After 16 weeks, 73% of patients in the treatment group versus 39% in…